Thalassemia is a genetic blood disorder characterized by reduced or absent production of hemoglobin, leading to anemia. Treatment approaches for thalassemia may include blood transfusions, iron chelation therapy, and, in severe cases, stem cell or bone marrow transplantation.
Latest Thalassemia Treatment Companies UpdateNov 2023: The world's inaugural gene therapy treatment for sickle cell disease has been approved by Britain's drugs authority, a development that may provide thousands of individuals in the country suffering from the debilitating illness with respite. According to a release, the first medication authorized to use the CRISPR gene editing technology, Casgevy, was approved by the Medicines and Healthcare Regulatory Agency. The product's creators were awarded the 2020 Nobel Prize. The commission approved using Casgevy, a drug produced by Boston-based Vertex Pharmaceuticals (Europe) Ltd. and CRISPR Therapeutics, as a treatment for individuals 12 and older with sickle cell disease and thalassemia. Up until now, the only permanent cure available has been bone marrow transplants, which are incredibly difficult operations with highly terrible side effects. To enable the body to produce healthy hemoglobin, the novel medication Casgevy targets the faulty gene in an individual's bone marrow stem cells. Patients undergo a round of chemotherapy before using stem cells from the individual's bone marrow and genetic editing techniques in a lab to correct the gene. After that, the patient receives a permanent treatment when the cells are reinfused. At least two hospital stays are required for patients: one for collecting stem cells and another for delivering the modified cells.List of Thalassemia Treatment Key companies in the market
Thalassemia Treatment Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)